Fusion heralds FDA tumor therapy clearance

By AuntMinnie.com staff writers

June 24, 2022 -- The U.S. Food and Drug Administration (FDA) has cleared Fusion Pharmaceuticals' investigational new drug applications for two tumor therapy agents, actinium-225 FPI-2059 (FPI-2059) and the corresponding imaging analog indium-111 FPI-2058 (FPI-2058).

FPI-2059 is an alpha therapy designed to use a small molecule to target and deliver actinium-225 to tumor sites expressing neurotensin receptor 1, which is a protein that is overexpressed in multiple solid tumor cancers such as colorectal, pancreatic, gastric, neuroendocrine differentiated prostate, head and neck squamous cell carcinoma, and Ewing sarcoma.

Fusion plans to initiate a phase I clinical trial in patients with solid tumors expressing neurotensin receptor 1 that will focus on six solid tumor indications, it said.


Copyright © 2022 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: